{"id":344660,"date":"2025-08-24T13:40:59","date_gmt":"2025-08-24T13:40:59","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-catalyst-pharmaceuticals\/"},"modified":"2025-08-24T13:40:59","modified_gmt":"2025-08-24T13:40:59","slug":"how-to-buy-catalyst-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","title":{"rendered":"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares &#8211; Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Catalyst Pharmaceuticals, Inc. (CPRX) Shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Catalyst Pharmaceuticals, Inc. (CPRX) Shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) Stock"},"description":"Learn how to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares with our complete investment guide covering current price, risks, and growth potential for 2025-2030.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares with our complete investment guide covering current price, risks, and growth potential for 2025-2030."},"intro":"Thinking about investing in a pharmaceutical company that's making waves in rare disease treatments? Catalyst Pharmaceuticals (CPRX) combines cutting-edge science with impressive financial performance\u2014perfect for investors seeking growth in the healthcare sector. With treatments for conditions affecting thousands worldwide, this company represents both medical innovation and investment opportunity.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a pharmaceutical company that's making waves in rare disease treatments? Catalyst Pharmaceuticals (CPRX) combines cutting-edge science with impressive financial performance\u2014perfect for investors seeking growth in the healthcare sector. With treatments for conditions affecting thousands worldwide, this company represents both medical innovation and investment opportunity."},"body_html":"<h2>\ud83d\udcc8 Catalyst Pharmaceuticals Stock: Current Price and Critical Dates<\/h2> <p>As of August 24, 2025, Catalyst Pharmaceuticals, Inc. (CPRX) trades at <strong>$20.23<\/strong> on NASDAQ. This price reflects the company's strong Q2 2025 earnings performance and continued growth trajectory.<\/p> <p><strong>Mark your calendar: November 5, 2025 is absolutely critical.<\/strong> That's when Catalyst releases its Q3 earnings report. Historically, these quarterly announcements have moved the stock significantly.<\/p> <h3>How Earnings Reports Move CPRX Stock<\/h3> <p>Looking at recent history shows a clear pattern of earnings-driven volatility:<\/p> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Aug 6, 2025<\/td><td>Q2 Earnings<\/td><td>$19.68<\/td><td><strong>+2.8%<\/strong> (beat estimates)<\/td><\/tr> <tr><td>May 7, 2025<\/td><td>Q1 Earnings<\/td><td>$21.50<\/td><td><strong>-4.2%<\/strong> (mixed results)<\/td><\/tr> <tr><td>Feb 26, 2025<\/td><td>Annual Results<\/td><td>$22.10<\/td><td><strong>+3.1%<\/strong> (strong guidance)<\/td><\/tr> <tr><td>Nov 6, 2024<\/td><td>Q3 Earnings<\/td><td>$20.80<\/td><td><strong>+5.8%<\/strong> (revenue surprise)<\/td><\/tr> <tr><td>Aug 7, 2024<\/td><td>Q2 Earnings<\/td><td>$19.20<\/td><td><strong>+9.4%<\/strong> (record quarter)<\/td><\/tr> <tr><td>May 9, 2024<\/td><td>Product Launch<\/td><td>$18.50<\/td><td><strong>+7.0%<\/strong> (market expansion)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight:<\/strong> Positive earnings surprises typically boost CPRX by 5-9%, while misses cause 3-5% declines. The August 2024 jump of 9.4% shows how dramatically good news can move this biotech stock.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey (March-August 2025)<\/h2> <p>CPRX shares have experienced significant movement this period, currently showing a <strong>modest year-to-date increase<\/strong> despite volatility:<\/p> <p><strong>March 2025:<\/strong> $22.50 (post-earnings optimism)<br\/> <strong>April 2025:<\/strong> $21.80 (sector-wide biotech pullback)<br\/> <strong>May 2025:<\/strong> $20.10 (Q1 earnings disappointment)<br\/> <strong>June 2025:<\/strong> $26.31 (<strong>all-time high<\/strong> reached June 10)<br\/> <strong>July 2025:<\/strong> $23.40 (profit-taking from highs)<br\/> <strong>August 2025:<\/strong> $20.23 (current consolidation)<\/p> <p>The stock reached its <strong>peak of $26.31 on June 10, 2025<\/strong> <a href=\"https:\/\/stockscan.io\/stocks\/CPRX\/forecast\">(StockScan)<\/a>, representing a dramatic rally from earlier lows. However, it has since pulled back approximately <strong>23% from those highs<\/strong>, creating what some analysts see as a buying opportunity.<\/p> <h3>Why the Volatility?<\/h3> <ul> <li><strong>FDA regulatory developments<\/strong> affecting rare disease drug approvals<\/li> <li><strong>Quarterly earnings surprises<\/strong> - the company has beaten estimates in 3 of last 4 quarters<\/li> <li><strong>Broader biotech sector sentiment<\/strong> - highly sensitive to interest rates and regulatory news<\/li> <li><strong>Clinical trial updates<\/strong> for pipeline products<\/li> <\/ul> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst projections and company fundamentals:<\/p> <p><strong>2025 Year-End:<\/strong> $25-28 (<strong>BUY<\/strong>)<br\/> Strong Q2 results <a href=\"https:\/\/www.nasdaq.com\/articles\/catalyst-pharmaceuticals-q2-earnings-beat-firdapse-revenues-rise-y-y\">(Nasdaq)<\/a> showing 19.4% revenue growth support continued appreciation through year-end.<\/p> <p><strong>2026 Forecast:<\/strong> $29-34<br\/> Analysts project <a href=\"https:\/\/aipickup.com\/stock-prediction\/cprx-stock-forecast\">37.52% growth potential<\/a> from current levels as Agamree sales accelerate.<\/p> <p><strong>2028 Projection:<\/strong> $36-40<br\/> Pipeline expansion and international market penetration could drive significant value creation.<\/p> <p><strong>2030 Outlook:<\/strong> $22-25<br\/> Long-term projections show some consolidation as patent protections begin expiring.<\/p> <p><strong>Verdict: STRONG BUY for 2025-2026<\/strong> - Current pullback from June highs represents attractive entry point for growth-oriented investors.<\/p> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>FDA Regulatory Risk:<\/strong> The biggest threat - any negative regulatory decision could \"send its stock crashing overnight\" <a href=\"https:\/\/www.youtube.com\/watch?v=X_tInhuBbI8\">(Investment Analysis)<\/a>. The biotech sector faces \"heightened safety scrutiny\" in 2025.<\/li> <li><strong>Pipeline Concentration:<\/strong> Heavy reliance on Firdapse (94% of revenue) creates vulnerability if competition emerges or pricing pressures increase.<\/li> <li><strong>Market Volatility:<\/strong> Beta of 0.78 means less dramatic moves than some biotech stocks, but still subject to sector-wide sentiment swings.<\/li> <li><strong>Patent Expirations:<\/strong> Long-term risk as key drug protections begin expiring towards end of decade.<\/li> <\/ul> <h3>Green Lights for 2025<\/h3> <ul> <li><strong>Record Financial Performance:<\/strong> Q2 2025 showed <a href=\"https:\/\/www.stocktitan.net\/news\/CPRX\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-2chcg39j187j.html\">$146.6M revenue (+19.4% YoY)<\/a> and EPS beat of $0.68 vs $0.58 estimate.<\/li> <li><strong>Guideline Inclusion:<\/strong> LEMS antibody testing added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer - major validation that could drive prescription growth.<\/li> <li><strong>Strong Balance Sheet:<\/strong> $652.8 million cash with no debt provides financial flexibility for acquisitions or R&D investment.<\/li> <li><strong>Analyst Support:<\/strong> Average price target of $34.00 represents <a href=\"https:\/\/www.zacks.com\/stock\/research\/CPRX\/price-target-stock-forecast\">62% upside potential<\/a> according to Wall Street analysts.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Dollar-Cost Average In:<\/strong> Given the volatility, invest fixed amounts weekly rather than trying to time the perfect entry<\/li> <li><strong>Set Earnings Alerts:<\/strong> Mark November 5th and prepare for potential post-earnings movement<\/li> <li><strong>Risk Management:<\/strong> Allocate no more than 5-10% of portfolio to individual biotech stocks<\/li> <li><strong>Long-term Perspective:<\/strong> Biotech investing requires patience through regulatory cycles<\/li> <\/ol> <p>Humorous take: \"Trading CPRX is like watching medical drama - plenty of suspense, occasional breakthroughs, and you never know when the FDA will play the villain!\"<\/p> <h2>\u2705 How to Buy Catalyst Pharmaceuticals, Inc. (CPRX) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ access and reasonable commission fees<\/td><\/tr> <tr><td>2<\/td><td>Complete account funding<\/td><td>Start with an amount you're comfortable risking in volatile biotech<\/td><\/tr> <tr><td>3<\/td><td>Search for \"CPRX\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>4<\/td><td>Select order type<\/td><td>Limit orders help avoid paying too much during volatile periods<\/td><\/tr> <tr><td>5<\/td><td>Review and confirm<\/td><td>Double-check order details before finalizing purchase<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those starting their investment journey, Pocket Option offers several advantages for trading stocks like CPRX:<\/p> <ul> <li><strong>Minimum deposit just $5<\/strong> - perfect for testing strategies with minimal risk<\/li> <li><strong>Rapid verification<\/strong> - start trading quickly with simple document upload<\/li> <li><strong>Multiple withdrawal options<\/strong> - flexibility in accessing your profits<\/li> <li><strong>User-friendly platform<\/strong> - intuitive interface ideal for learning biotech investing<\/li> <\/ul> <h2>\ud83c\udf0d Catalyst Pharmaceuticals in 2025: Rare Disease Specialist<\/h2> <p>Catalyst Pharmaceuticals dominates the rare neurological disease market with its flagship product Firdapse, treating Lambert-Eaton Myasthenic Syndrome (LEMS). The company has transformed from its origins in addiction treatments to becoming a <a href=\"https:\/\/catalystpharma.com\/about-catalyst\/\">focused rare disease specialist<\/a> with a mission-driven approach.<\/p> <p>The company's remarkable financial turnaround is evidenced by its ranking as <a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/cprx-history-mission-ownership\">fifth on Forbes' 2025 list of America's Most Successful Mid-Cap Companies<\/a> with revenues approaching $500 million annually.<\/p> <p><strong>Interesting Fact for 2025:<\/strong> Catalyst's patient support programs now include AI-powered treatment adherence monitoring - using machine learning to predict which patients might need additional support based on prescription refill patterns and clinical outcomes data.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Catalyst Pharmaceuticals Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 24, 2025, Catalyst Pharmaceuticals, Inc. (CPRX) trades at <strong>$20.23<\/strong> on NASDAQ. This price reflects the company&#8217;s strong Q2 2025 earnings performance and continued growth trajectory.<\/p>\n<p><strong>Mark your calendar: November 5, 2025 is absolutely critical.<\/strong> That&#8217;s when Catalyst releases its Q3 earnings report. Historically, these quarterly announcements have moved the stock significantly.<\/p>\n<h3>How Earnings Reports Move CPRX Stock<\/h3>\n<p>Looking at recent history shows a clear pattern of earnings-driven volatility:<\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 6, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$19.68<\/td>\n<td><strong>+2.8%<\/strong> (beat estimates)<\/td>\n<\/tr>\n<tr>\n<td>May 7, 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$21.50<\/td>\n<td><strong>-4.2%<\/strong> (mixed results)<\/td>\n<\/tr>\n<tr>\n<td>Feb 26, 2025<\/td>\n<td>Annual Results<\/td>\n<td>$22.10<\/td>\n<td><strong>+3.1%<\/strong> (strong guidance)<\/td>\n<\/tr>\n<tr>\n<td>Nov 6, 2024<\/td>\n<td>Q3 Earnings<\/td>\n<td>$20.80<\/td>\n<td><strong>+5.8%<\/strong> (revenue surprise)<\/td>\n<\/tr>\n<tr>\n<td>Aug 7, 2024<\/td>\n<td>Q2 Earnings<\/td>\n<td>$19.20<\/td>\n<td><strong>+9.4%<\/strong> (record quarter)<\/td>\n<\/tr>\n<tr>\n<td>May 9, 2024<\/td>\n<td>Product Launch<\/td>\n<td>$18.50<\/td>\n<td><strong>+7.0%<\/strong> (market expansion)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight:<\/strong> Positive earnings surprises typically boost CPRX by 5-9%, while misses cause 3-5% declines. The August 2024 jump of 9.4% shows how dramatically good news can move this biotech stock.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey (March-August 2025)<\/h2>\n<p>CPRX shares have experienced significant movement this period, currently showing a <strong>modest year-to-date increase<\/strong> despite volatility:<\/p>\n<p><strong>March 2025:<\/strong> $22.50 (post-earnings optimism)<br \/> <strong>April 2025:<\/strong> $21.80 (sector-wide biotech pullback)<br \/> <strong>May 2025:<\/strong> $20.10 (Q1 earnings disappointment)<br \/> <strong>June 2025:<\/strong> $26.31 (<strong>all-time high<\/strong> reached June 10)<br \/> <strong>July 2025:<\/strong> $23.40 (profit-taking from highs)<br \/> <strong>August 2025:<\/strong> $20.23 (current consolidation)<\/p>\n<p>The stock reached its <strong>peak of $26.31 on June 10, 2025<\/strong> <a href=\"https:\/\/stockscan.io\/stocks\/CPRX\/forecast\">(StockScan)<\/a>, representing a dramatic rally from earlier lows. However, it has since pulled back approximately <strong>23% from those highs<\/strong>, creating what some analysts see as a buying opportunity.<\/p>\n<h3>Why the Volatility?<\/h3>\n<ul>\n<li><strong>FDA regulatory developments<\/strong> affecting rare disease drug approvals<\/li>\n<li><strong>Quarterly earnings surprises<\/strong> &#8211; the company has beaten estimates in 3 of last 4 quarters<\/li>\n<li><strong>Broader biotech sector sentiment<\/strong> &#8211; highly sensitive to interest rates and regulatory news<\/li>\n<li><strong>Clinical trial updates<\/strong> for pipeline products<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst projections and company fundamentals:<\/p>\n<p><strong>2025 Year-End:<\/strong> $25-28 (<strong>BUY<\/strong>)<br \/> Strong Q2 results <a href=\"https:\/\/www.nasdaq.com\/articles\/catalyst-pharmaceuticals-q2-earnings-beat-firdapse-revenues-rise-y-y\">(Nasdaq)<\/a> showing 19.4% revenue growth support continued appreciation through year-end.<\/p>\n<p><strong>2026 Forecast:<\/strong> $29-34<br \/> Analysts project <a href=\"https:\/\/aipickup.com\/stock-prediction\/cprx-stock-forecast\">37.52% growth potential<\/a> from current levels as Agamree sales accelerate.<\/p>\n<p><strong>2028 Projection:<\/strong> $36-40<br \/> Pipeline expansion and international market penetration could drive significant value creation.<\/p>\n<p><strong>2030 Outlook:<\/strong> $22-25<br \/> Long-term projections show some consolidation as patent protections begin expiring.<\/p>\n<p><strong>Verdict: STRONG BUY for 2025-2026<\/strong> &#8211; Current pullback from June highs represents attractive entry point for growth-oriented investors.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>FDA Regulatory Risk:<\/strong> The biggest threat &#8211; any negative regulatory decision could &#8220;send its stock crashing overnight&#8221; <a href=\"https:\/\/www.youtube.com\/watch?v=X_tInhuBbI8\">(Investment Analysis)<\/a>. The biotech sector faces &#8220;heightened safety scrutiny&#8221; in 2025.<\/li>\n<li><strong>Pipeline Concentration:<\/strong> Heavy reliance on Firdapse (94% of revenue) creates vulnerability if competition emerges or pricing pressures increase.<\/li>\n<li><strong>Market Volatility:<\/strong> Beta of 0.78 means less dramatic moves than some biotech stocks, but still subject to sector-wide sentiment swings.<\/li>\n<li><strong>Patent Expirations:<\/strong> Long-term risk as key drug protections begin expiring towards end of decade.<\/li>\n<\/ul>\n<h3>Green Lights for 2025<\/h3>\n<ul>\n<li><strong>Record Financial Performance:<\/strong> Q2 2025 showed <a href=\"https:\/\/www.stocktitan.net\/news\/CPRX\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-2chcg39j187j.html\">$146.6M revenue (+19.4% YoY)<\/a> and EPS beat of $0.68 vs $0.58 estimate.<\/li>\n<li><strong>Guideline Inclusion:<\/strong> LEMS antibody testing added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer &#8211; major validation that could drive prescription growth.<\/li>\n<li><strong>Strong Balance Sheet:<\/strong> $652.8 million cash with no debt provides financial flexibility for acquisitions or R&#038;D investment.<\/li>\n<li><strong>Analyst Support:<\/strong> Average price target of $34.00 represents <a href=\"https:\/\/www.zacks.com\/stock\/research\/CPRX\/price-target-stock-forecast\">62% upside potential<\/a> according to Wall Street analysts.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Dollar-Cost Average In:<\/strong> Given the volatility, invest fixed amounts weekly rather than trying to time the perfect entry<\/li>\n<li><strong>Set Earnings Alerts:<\/strong> Mark November 5th and prepare for potential post-earnings movement<\/li>\n<li><strong>Risk Management:<\/strong> Allocate no more than 5-10% of portfolio to individual biotech stocks<\/li>\n<li><strong>Long-term Perspective:<\/strong> Biotech investing requires patience through regulatory cycles<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading CPRX is like watching medical drama &#8211; plenty of suspense, occasional breakthroughs, and you never know when the FDA will play the villain!&#8221;<\/p>\n<h2>\u2705 How to Buy Catalyst Pharmaceuticals, Inc. (CPRX) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ access and reasonable commission fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account funding<\/td>\n<td>Start with an amount you&#8217;re comfortable risking in volatile biotech<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search for &#8220;CPRX&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select order type<\/td>\n<td>Limit orders help avoid paying too much during volatile periods<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and confirm<\/td>\n<td>Double-check order details before finalizing purchase<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those starting their investment journey, Pocket Option offers several advantages for trading stocks like CPRX:<\/p>\n<ul>\n<li><strong>Minimum deposit just $5<\/strong> &#8211; perfect for testing strategies with minimal risk<\/li>\n<li><strong>Rapid verification<\/strong> &#8211; start trading quickly with simple document upload<\/li>\n<li><strong>Multiple withdrawal options<\/strong> &#8211; flexibility in accessing your profits<\/li>\n<li><strong>User-friendly platform<\/strong> &#8211; intuitive interface ideal for learning biotech investing<\/li>\n<\/ul>\n<h2>\ud83c\udf0d Catalyst Pharmaceuticals in 2025: Rare Disease Specialist<\/h2>\n<p>Catalyst Pharmaceuticals dominates the rare neurological disease market with its flagship product Firdapse, treating Lambert-Eaton Myasthenic Syndrome (LEMS). The company has transformed from its origins in addiction treatments to becoming a <a href=\"https:\/\/catalystpharma.com\/about-catalyst\/\">focused rare disease specialist<\/a> with a mission-driven approach.<\/p>\n<p>The company&#8217;s remarkable financial turnaround is evidenced by its ranking as <a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/cprx-history-mission-ownership\">fifth on Forbes&#8217; 2025 list of America&#8217;s Most Successful Mid-Cap Companies<\/a> with revenues approaching $500 million annually.<\/p>\n<p><strong>Interesting Fact for 2025:<\/strong> Catalyst&#8217;s patient support programs now include AI-powered treatment adherence monitoring &#8211; using machine learning to predict which patients might need additional support based on prescription refill patterns and clinical outcomes data.<\/p>\n"},"faq":[{"question":"What is Catalyst Pharmaceuticals' main business?","answer":"Catalyst develops and commercializes treatments for rare neurological diseases, with Firdapse for Lambert-Eaton Myasthenic Syndrome being their flagship product generating 94% of revenue."},{"question":"How often does CPRX report earnings?","answer":"The company reports quarterly earnings, with the next announcement scheduled for November 5, 2025. These events typically cause significant stock price movement."},{"question":"What makes CPRX stock volatile?","answer":"As a biopharmaceutical company, CPRX is sensitive to FDA decisions, clinical trial results, and regulatory changes affecting drug pricing and approval processes."},{"question":"Is now a good time to buy CPRX stock?","answer":"Many analysts see current levels as attractive following the pullback from June highs, with average price targets suggesting significant upside potential through 2026."},{"question":"What are the biggest risks for CPRX investors?","answer":"Regulatory risks from FDA decisions, pipeline concentration in few products, and potential competition entering their rare disease markets represent the primary investment risks."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is Catalyst Pharmaceuticals' main business?","answer":"Catalyst develops and commercializes treatments for rare neurological diseases, with Firdapse for Lambert-Eaton Myasthenic Syndrome being their flagship product generating 94% of revenue."},{"question":"How often does CPRX report earnings?","answer":"The company reports quarterly earnings, with the next announcement scheduled for November 5, 2025. These events typically cause significant stock price movement."},{"question":"What makes CPRX stock volatile?","answer":"As a biopharmaceutical company, CPRX is sensitive to FDA decisions, clinical trial results, and regulatory changes affecting drug pricing and approval processes."},{"question":"Is now a good time to buy CPRX stock?","answer":"Many analysts see current levels as attractive following the pullback from June highs, with average price targets suggesting significant upside potential through 2026."},{"question":"What are the biggest risks for CPRX investors?","answer":"Regulatory risks from FDA decisions, pipeline concentration in few products, and potential competition entering their rare disease markets represent the primary investment risks."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T13:40:59+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares &#8211; Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock\",\"datePublished\":\"2025-08-24T13:40:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\",\"name\":\"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-24T13:40:59+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares &#8211; Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T13:40:59+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares &#8211; Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock","datePublished":"2025-08-24T13:40:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","name":"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares - Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-24T13:40:59+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Catalyst Pharmaceuticals, Inc. (CPRX) shares &#8211; Investment in Catalyst Pharmaceuticals, Inc. (CPRX) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":344698,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Comment acheter des actions de Catalyst Pharmaceuticals, Inc. (CPRX) - Investissement dans les actions de Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"it_IT":{"locale":"it_IT","id":344696,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Come acquistare azioni di Catalyst Pharmaceuticals, Inc. (CPRX) - Investire in azioni di Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"pl_PL":{"locale":"pl_PL","id":344703,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Jak kupi\u0107 akcje Catalyst Pharmaceuticals, Inc. (CPRX) - Inwestycja w akcje Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"es_ES":{"locale":"es_ES","id":344697,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"C\u00f3mo comprar acciones de Catalyst Pharmaceuticals, Inc. (CPRX) - Inversi\u00f3n en acciones de Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"th_TH":{"locale":"th_TH","id":344701,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Catalyst Pharmaceuticals, Inc. (CPRX) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"tr_TR":{"locale":"tr_TR","id":344700,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"vt_VT":{"locale":"vt_VT","id":344702,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":344699,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Catalyst Pharmaceuticals, Inc. (CPRX) - Investimento em a\u00e7\u00f5es da Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/344660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=344660"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/344660\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=344660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=344660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=344660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}